Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data
Top Cited Papers
- 17 August 2011
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 3 (96) , 96ra77
- https://doi.org/10.1126/scitranslmed.3001318
Abstract
A systematic computational method predicts new uses for existing drugs by integrating public gene expression signatures of drugs and diseases.This publication has 76 references indexed in Scilit:
- Predicting new molecular targets for known drugsNature, 2009
- Data-Driven Methods to Discover Molecular Determinants of Serious Adverse Drug EventsClinical Pharmacology & Therapeutics, 2009
- Disease signatures are robust across tissues and experimentsMolecular Systems Biology, 2009
- Comparative analysis of gene expression profiles between the normal human cartilage and the one with endemic osteoarthritisOsteoarthritis and Cartilage, 2008
- Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitroCancer Letters, 2008
- AILUN: reannotating gene expression data automaticallyNature Methods, 2007
- [19] Gene Expression Omnibus: Microarray Data Storage, Submission, Retrieval, and AnalysisPublished by Elsevier ,2006
- Creation and implications of a phenome-genome networkNature Biotechnology, 2006
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003